PMID: 11925533Apr 2, 2002Paper

Acute myelogenous leukemia: advances and limitations of treatment

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
Ernesta ParisiThomas P Sollecito

Abstract

Acute myelogenous leukemia (AML) describes a group of related hematologic malignancies that are being approached therapeutically from several perspectives. Conventional chemotherapeutic agents, such as anthracyclines and cytosine arabinoside (Ara-C), are useful in treating AML but now appear to have reached their maximum potential. Newer therapeutic approaches to AML have recently focused on immune-based therapy through monoclonal antibodies that target and destroy malignant cells via specific cell receptors. One such agent is gemtuzumab (CMA-676), an agent that targets the CD33 antigen on malignant myeloid cells. Initial studies have shown significant anticancer activity. We will discuss traditional and newer therapeutic approaches to AML and review the role of monoclonal antibody based therapies for patients with AML. A case of a 30-year-old man with refractory AML who was treated with gemtuzumab will be mentioned, highlighting potential applications and possible limitations to this novel therapy. Despite the effective reduction in the number of malignant cells in bone marrow, gemtuzumab ineffectively treated extramedullary leukemic gingival infiltrate. Regardless of limitations, monoclonal-based therapy offers an exciting an...Continue Reading

References

May 1, 1990·Journal of Neurosurgery·W H Hall
May 1, 1995·Hematological Oncology·D Rubio-FelixM Giralt
Oct 3, 1998·Bone Marrow Transplantation·J M DarvilleA B Foot
Sep 24, 1999·Leukemia & Lymphoma·M BaudardR Zittoun
Nov 30, 1999·Hematology/oncology Clinics of North America·B Spellberg, G J Schiller
Nov 30, 1999·Hematology/oncology Clinics of North America·L Popplewell, S J Forman
Feb 16, 2000·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·S J McKenna
Apr 18, 2000·Journal of Clinical Pathology·M W Lowdell, M B Koh
Apr 5, 2001·The New England Journal of Medicine·B J DrukerC L Sawyers
Jun 12, 2002·Current Treatment Options in Oncology·M R Litzow

❮ Previous
Next ❯

Citations

Oct 4, 2002·Hematological Oncology
Mar 19, 2003·Proceedings of the National Academy of Sciences of the United States of America·Heping ZhangBurton Singer
Jun 18, 2004·Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·Eric T StooplerThomas P Sollecito
Aug 28, 2009·Australian Dental Journal·F A SantosF C Groppo
Feb 21, 2009·Australian Dental Journal·P KoulocherisB Hohlweg-Majert
Jan 5, 2010·The Journal of the American Dental Association·Scott S DeRossiFaizan Alawi
Aug 8, 2021·International Journal of Environmental Research and Public Health·Maja PtasiewiczRenata Chałas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.